Skip to content


Vizimpro (dacomitinib) is a small molecule pharmaceutical. Dacomitinib was first approved as Vizimpro on 2018-09-27. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. It is known to target receptor tyrosine-protein kinase erbB-4, epidermal growth factor receptor, and receptor tyrosine-protein kinase erbB-2. Vizimpro's patents are valid until 2028-08-26 (FDA).
Trade Name Vizimpro
Common Name Dacomitinib
Indication non-small-cell lung carcinoma
Drug Class Tyrosine kinase inhibitors
Get full access now